Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.

A series of new HIV-1 protease inhibitors (PIs) were designed using a general strategy that combines computational structure-based design with substrate-envelope constraints. The PIs incorporate various alcohol-derived P2 carbamates with acyclic and cyclic heteroatomic functionalities into the (R)-hydroxyethylamine isostere. Most of the new PIs show potent binding affinities against wild-type HIV-1 protease and three multidrug resistant (MDR) variants. In particular, inhibitors containing the 2,2-dichloroacetamide, pyrrolidinone, imidazolidinone, and oxazolidinone moieties at P2 are the most potent with K(i) values in the picomolar range. Several new PIs exhibit nanomolar antiviral potencies against patient-derived wild-type viruses from HIV-1 clades A, B, and C and two MDR variants. Crystal structure analyses of four potent inhibitors revealed that carbonyl groups of the new P2 moieties promote extensive hydrogen bond interactions with the invariant Asp29 residue of the protease. These structure-activity relationship findings can be utilized to design new PIs with enhanced enzyme inhibitory and antiviral potencies.

[1]  William A. Lee,et al.  Discovery of GS-8374, a potent human immunodeficiency virus type 1 protease inhibitor with a superior resistance profile , 2011 .

[2]  Arun K. Ghosh,et al.  Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation. , 2011, Journal of medicinal chemistry.

[3]  C. Schiffer,et al.  Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. , 2010, Journal of medicinal chemistry.

[4]  B. Kuhn,et al.  A Medicinal Chemist’s Guide to Molecular Interactions , 2010, Journal of medicinal chemistry.

[5]  Michael K. Gilson,et al.  Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug Resistance , 2010, Journal of Virology.

[6]  E. Freire.  Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.

[7]  Irene T Weber,et al.  Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. , 2008, Journal of medicinal chemistry.

[8]  Hong Cao,et al.  HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. , 2008, Journal of the American Chemical Society.

[9]  L. Waters,et al.  Why do patients fail HIV therapy? , 2007, International journal of clinical practice.

[10]  Akbar Ali,et al.  Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. , 2006, Journal of medicinal chemistry.

[11]  Arun K. Ghosh,et al.  Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. , 2006, Journal of medicinal chemistry.

[12]  M. Hanlon,et al.  Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. , 2006, Bioorganic & medicinal chemistry letters.

[13]  Arun K. Ghosh,et al.  Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. , 2006, Journal of medicinal chemistry.

[14]  Dirk Jochmans,et al.  TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[15]  Celia A Schiffer,et al.  Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. , 2005, Journal of medicinal chemistry.

[16]  Celia A Schiffer,et al.  Design of HIV-1 protease inhibitors active on multidrug-resistant virus. , 2005, Journal of medicinal chemistry.

[17]  Celia A. Schiffer,et al.  Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor , 2004, Journal of Virology.

[18]  N. Ford,et al.  HIV drug resistance. , 2004, The New England journal of medicine.

[19]  Irene T. Weber,et al.  Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[20]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[21]  C. Schiffer,et al.  Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. , 2002, Structure.

[22]  Celia A Schiffer,et al.  Lack of synergy for inhibitors targeting a multi‐drug‐resistant HIV‐1 protease , 2002, Protein science : a publication of the Protein Society.

[23]  Joseph Quinn,et al.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.

[24]  C. Schiffer,et al.  How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. , 2000, Journal of molecular biology.

[25]  J. Mellors,et al.  3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine , 2000, Annals of Internal Medicine.

[26]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[27]  A R Leach,et al.  Exploring the conformational space of protein side chains using dead‐end elimination and the A* algorithm , 1998, Proteins.

[28]  Bruce Tidor,et al.  Optimizing electrostatic affinity in ligand-receptor binding: Theory, computation, and ligand properties , 1998 .

[29]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[30]  R. Hogg,et al.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.

[31]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[32]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[33]  K. Sharp,et al.  Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .

[34]  F. Momany,et al.  Validation of the general purpose QUANTA ®3.2/CHARMm® force field , 1992 .

[35]  Johan Desmet,et al.  The dead-end elimination theorem and its use in protein side-chain positioning , 1992, Nature.

[36]  J Kuriyan,et al.  Rigid protein motion as a model for crystallographic temperature factors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Honig,et al.  A rapid finite difference algorithm, utilizing successive over‐relaxation to solve the Poisson–Boltzmann equation , 1991 .

[38]  Gary T. Wang,et al.  Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. , 1990, Science.

[39]  K. Sharp,et al.  Calculating the electrostatic potential of molecules in solution: Method and error assessment , 1988 .

[40]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[41]  W. Greco,et al.  Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors. , 1979, The Journal of biological chemistry.

[42]  K. N. Trueblood,et al.  On the rigid-body motion of molecules in crystals , 1968 .

[43]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[44]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[45]  M. Murcko,et al.  Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .

[46]  B. Honig,et al.  Calculation of the total electrostatic energy of a macromolecular system: Solvation energies, binding energies, and conformational analysis , 1988, Proteins.